Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
1. A method of eliciting an immune response in a patient who has prostate cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells, which present a peptide consisting of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO: 49),
wherein the peptide is in a complex with an MHC molecule,
wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell,
wherein the activated T cells are expanded in vitro in the presence of an anti-CD28 antibody and IL-12.
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.
4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , wherein the MHC molecule is a class I MHC molecule.
6. The method of claim 1 , wherein the activated T cells are expanded in the presence of IL-12.
7. The method of claim 1 , wherein the antigen presenting cell is infected with recombinant virus expressing the peptide.
8. The method of claim 7 , wherein the antigen presenting cell is a dendritic cell or a macrophage.
9. The method of claim 1 , wherein the contacting is in vitro.
10. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.
11. The method of claim 10 , wherein the composition further comprises an adjuvant.
12. The method of claim 11 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formations formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
13. The method of claim 1 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO: 49).
14. The method of claim 13 , wherein the immune response comprises a cytotoxic T cell response.
15. The method of claim 1 , wherein the antigen presenting cell is a particle coated with the peptide in a complex with an WIC class I molecule, wherein the particle is polystyrene particle.
16. The method of claim 15 , wherein the particle further comprises an anti-CD28 antibody.